SAN DIEGO, March 8, 2018 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (NASDAQ: ARNA), will announce its fourth
quarter and full-year 2017 financial results on Wednesday, March 14, 2018, before the open of the
U.S. financial markets. The Company will host a conference
call and live webcast to discuss the results with the investment
community the same day at 8:30 a.m.
EDT.
Conference Call & Webcast Information
When:
March 14, 2018, 8:30 a.m. EDT
Dial-in: (877) 643-7155 (United
States) or (914) 495-8552 (International)
Conference ID: 2074279
Please join the conference call at least 10 minutes early to
register. You can access the live webcast under the investor
relations section of Arena's website at:
www.arenapharm.com. A replay of the conference call will be
archived under the investor relations section of Arena's website
for 30 days after the call.
About Arena Pharmaceuticals
Arena Pharmaceuticals is
focused on developing novel, small molecule drugs with optimized
receptor pharmacology and pharmacokinetics designed to deliver
broad clinical utility across several therapeutic areas. Arena's
proprietary pipeline includes potentially first- or best-in-class
programs. The most advanced investigational clinical programs
are ralinepag (APD811), which will be commencing a Phase 3 program
for pulmonary arterial hypertension (PAH), and etrasimod (APD334),
which is in Phase 2 for a broad range of immune and inflammatory
conditions. Arena is also evaluating APD371 in Phase 2 for
the treatment of pain associated with Crohn's disease. In addition,
Arena has collaborations with the following pharmaceutical
companies: Everest Medicines Limited (ralinepag and etrasimod in
Greater China and select Asian
countries), Axovant Sciences GmbH (nelotanserin - Phase 2),
Boehringer Ingelheim International GmbH (undisclosed target -
preclinical), and Eisai Co., Ltd. and Eisai Inc.
(BELVIQ® - marketed product).
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. Such forward-looking statements include
statements about Arena's financial results announcement, focus, and
the potential of its programs and collaborations. For such
statements, Arena claims the protection of the Private Securities
Litigation Reform Act of 1995. Actual events or results may differ
materially from Arena's expectations. Factors that could cause
actual results to differ materially from the forward-looking
statements include those disclosed in Arena's filings with the
Securities and Exchange Commission. These forward-looking
statements represent Arena's judgment as of the time of this
release. Arena disclaims any intent or obligation to update these
forward-looking statements, other than as may be required under
applicable law.
Corporate Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial Officer
klind@arenapharm.com
858.210.3636
Media Contact:
Matt Middleman, M.D.
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
View original content with
multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2017-financial-results-and-provide-corporate-update-on-wednesday-march-14-300610510.html
SOURCE Arena Pharmaceuticals, Inc.